Repligen (NASDAQ:RGEN) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, BidAskClub reports.

RGEN has been the subject of several other reports. Zacks Investment Research raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday, February 27th. CL King raised shares of Repligen from a “neutral” rating to a “buy” rating in a research note on Monday, December 17th. They noted that the move was a valuation call. Finally, ValuEngine downgraded shares of Repligen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 4th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. Repligen has an average rating of “Buy” and an average price target of $59.20.

Repligen stock opened at $58.24 on Tuesday. The firm has a market capitalization of $2.49 billion, a price-to-earnings ratio of 76.61, a price-to-earnings-growth ratio of 3.90 and a beta of 1.08. Repligen has a twelve month low of $36.10 and a twelve month high of $70.50.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 21st. The biotechnology company reported $0.21 earnings per share for the quarter, hitting the consensus estimate of $0.21. The business had revenue of $51.90 million during the quarter, compared to the consensus estimate of $50.27 million. Repligen had a net margin of 8.56% and a return on equity of 5.51%. The firm’s revenue for the quarter was up 24.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.20 earnings per share. On average, equities analysts anticipate that Repligen will post 0.83 EPS for the current fiscal year.

In other news, CEO Anthony Hunt sold 7,475 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $59.01, for a total transaction of $441,099.75. Following the completion of the transaction, the chief executive officer now directly owns 250,132 shares of the company’s stock, valued at $14,760,289.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jon Snodgres sold 1,875 shares of the company’s stock in a transaction dated Thursday, February 28th. The shares were sold at an average price of $58.88, for a total transaction of $110,400.00. Following the transaction, the chief financial officer now directly owns 26,821 shares of the company’s stock, valued at $1,579,220.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,437 shares of company stock valued at $2,855,032. Insiders own 1.40% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Huntington National Bank bought a new position in Repligen in the first quarter worth about $25,000. First Hawaiian Bank bought a new position in Repligen in the fourth quarter worth about $28,000. Enlightenment Research LLC bought a new position in Repligen in the fourth quarter worth about $42,000. Parallel Advisors LLC raised its stake in Repligen by 485.1% in the fourth quarter. Parallel Advisors LLC now owns 1,258 shares of the biotechnology company’s stock worth $66,000 after buying an additional 1,043 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. raised its stake in Repligen by 16.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after buying an additional 214 shares in the last quarter. 91.26% of the stock is owned by institutional investors.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: Options Trading – What is a Straddle?

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.